Spots Global Cancer Trial Database for tolerability
Every month we try and update this database with for tolerability cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma | NCT04324840 | Glioblastoma | CC-90010 Temozolomide Radiotherapy | 18 Years - | Celgene | |
| Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability | NCT02663193 | Prostate Cancer | No Intervention | 18 Years - | Janssen Scientific Affairs, LLC | |
| Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 | NCT03644459 | Ovarian Cancer Cervical Cancer Colorectal Canc... Stomach Cancer | LYN00101 | 18 Years - 80 Years | Lynkcell Inc. | |
| Capivasertib China PK Study | NCT04742036 | Advanced Solid ... | Capivasertib Paclitaxel | 18 Years - 130 Years | AstraZeneca | |
| Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors | NCT01031719 | H1N1 Influenza ... Invasive Solid ... | adjuvanted A(H1... non-adjuvanted ... non-adjuvanted ... | 2 Years - 70 Years | Chiltern Pesquisa Clinica Ltda | |
| Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation | NCT06243354 | Safety Tolerability Efficacy | Test product: H... | 18 Years - | Sichuan Huiyu Pharmaceutical Co., Ltd | |
| A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments | NCT05152472 | Unresectable Ga... Locally Advance... Metastatic Gast... | Atezolizumab 12... Imatinib 400 MG | 18 Years - | Centre Leon Berard | |
| Capivasertib China PK Study | NCT04742036 | Advanced Solid ... | Capivasertib Paclitaxel | 18 Years - 130 Years | AstraZeneca | |
| Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors | NCT04088604 | Advanced Solid ... | LY01610 ( Irino... LY01610 ( Irino... Irinotecan Hydr... | 18 Years - 70 Years | Luye Pharma Group Ltd. | |
| A Study of ASP2138 in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, Pancreatic Cancer | NCT05365581 | Gastric Adenoca... Gastroesophagea... Pancreatic Aden... | ASP2138 | 18 Years - | Astellas Pharma Inc | |
| The Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus | NCT01905202 | Barrett's Esoph... | Secretrol | 18 Years - | Effexus Pharmaceutical | |
| An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations | NCT02192697 | Non-small Cell ... | ASP8273 | 20 Years - | Astellas Pharma Inc | |
| First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma | NCT04116658 | Glioblastoma, A... | Multiple dose o... | 18 Years - | Enterome | |
| First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma | NCT04116658 | Glioblastoma, A... | Multiple dose o... | 18 Years - | Enterome | |
| Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia | NCT02316197 | Advanced Solid ... Chronic Lymphoc... | MSC2490484A (M3... | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404 | NCT01240642 | Metastatic Canc... Metastatic Canc... | ASA404 | 18 Years - | Novartis | |
| Ispinesib In Combination With Capecitabine In Patients With Solid Tumors | NCT00119171 | Solid Tumor Can... | Ispinesib Capecitabine | 18 Years - | GlaxoSmithKline | |
| A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma | NCT03528629 | Gastric Cancer Gastro-esophage... | Zolbetuximab | 20 Years - | Astellas Pharma Inc | |
| An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies | NCT05469919 | Advanced Solid ... | Ceralasertib | 18 Years - | AstraZeneca | |
| Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis | NCT02242747 | Actinic Keratos... | ingenol mebutat... 5% 5-FU | 18 Years - | University of Sao Paulo | |
| IPG7236 in Patients With Advanced Solid Tumors | NCT05142592 | Safety Issues Tolerability Pharmacokinetic... | IPG7236 | 18 Years - | Nanjing Immunophage Biotech Co., Ltd | |
| TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms | NCT03503968 | Safety Tolerability Feasibility Treatment Effic... | MDG1011 Investigator Ch... | 18 Years - | Medigene AG | |
| Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma | NCT05622136 | Liver Cancer Hepatocellular ... | Regorafenib Ora... | 18 Years - | Instituto do Cancer do Estado de São Paulo | |
| Study of BEBT-908 in Subjects With Advanced Hematological Tumors | NCT06082596 | Relapsed or Ref... Relapsed or Ref... | BEBT-908 for in... | 18 Years - 70 Years | BeBetter Med Inc | |
| Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation | NCT06243354 | Safety Tolerability Efficacy | Test product: H... | 18 Years - | Sichuan Huiyu Pharmaceutical Co., Ltd | |
| Ispinesib In Combination With Carboplatin In Patients With Solid Tumors | NCT00136578 | Solid Tumours | SB-715992 carboplatin | 18 Years - | GlaxoSmithKline | |
| A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function | NCT01278758 | Metastatic Canc... | ASA404, DMXAA o... | 18 Years - | Novartis | |
| A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors | NCT01299701 | Advanced Solid ... | ASA404 | 18 Years - | Novartis | |
| Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer | NCT01972737 | Colon Cancer | Ad5-hGCC-PADRE ... | 18 Years - | Thomas Jefferson University | |
| Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma | NCT00625768 | Metastatic Rena... Metastatic Mali... | AS1409 | 18 Years - | Antisoma Research | |
| Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects | NCT02054754 | Safety Tolerability Pharmacokinetic... Cancer | Dexanabinol Dos... Dexanabinol Dos... Dexanabinol Dos... Dexanabinol Dos... Dexanabinol Dos... Placebo | 18 Years - 45 Years | e-Therapeutics PLC | |
| A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas | NCT01900158 | Cholangiocarcin... | Amphinex, Gemci... | 18 Years - | PCI Biotech AS | |
| Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors | NCT02746081 | Solid Tumors | BAY1436032 | 18 Years - | Bayer | |
| AZD9291 in Combination With Ascending Doses of Novel Therapeutics | NCT02143466 | Advanced Non Sm... | Part A - AZD929... Part A - AZD929... Part A - AZD929... Part A - AZD929... Part A - AZD929... Part B - AZD929... Part B - AZD929... Part B - AZD929... Part C - AZD609... Part C - AZD929... Part D - AZD929... | 18 Years - 130 Years | AstraZeneca | |
| Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination | NCT01585870 | Neoplasms | Sorafenib (Nexa... Eribulin | 18 Years - | Bayer | |
| A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast | NCT02897700 | Breast Cancer | Single agent of... cyclophosphamid... Placebo | 18 Years - | Shanghai Jiao Tong University School of Medicine | |
| Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination | NCT01585870 | Neoplasms | Sorafenib (Nexa... Eribulin | 18 Years - | Bayer | |
| A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma | NCT04324840 | Glioblastoma | CC-90010 Temozolomide Radiotherapy | 18 Years - | Celgene | |
| PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment | NCT02864030 | Metastatic Brea... Toxicity Neurotoxicity Drug Toxicity Adverse Drug Ev... | ERIBULIN MESYLA... | 18 Years - | Oncologia Medica dell'Ospedale Fatebenefratelli | |
| The TRANSLATE Trial | NCT05179694 | Prostate Cancer | Prostate biopsy | 18 Years - | University of Oxford | |
| Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML) | NCT01247493 | Acute Myeloid L... | induction chemo... | 60 Years - | Seoul National University Hospital | |
| Absorption and Tolerability Studies of an Emulsion Containing the Coconut Oil-derived Glycerol Tridecanoate in Healthy Men | NCT03255889 | Polycystic Ovar... | Glyceryl Tridec... Placebo | 21 Years - 40 Years | National University Hospital, Singapore | |
| An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404 | NCT01240642 | Metastatic Canc... Metastatic Canc... | ASA404 | 18 Years - | Novartis | |
| A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas | NCT01900158 | Cholangiocarcin... | Amphinex, Gemci... | 18 Years - | PCI Biotech AS | |
| Ponatinib in CML Patients in Chronic Phase | NCT06119269 | Chronic Myeloid... | Therapeutic dru... Molecular Respo... | 18 Years - | University of Pisa | |
| Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors | NCT00874042 | Advanced Solid ... | Treatment with ... | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain | NCT03435341 | Leukemia, Myelo... | 60 Years - | Celgene | ||
| Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors | NCT00827177 | Advanced Solid ... | Treatment with ... | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors | NCT02630251 | Cancer Neoplasms | GSK2820151 | 18 Years - | GlaxoSmithKline | |
| Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma | NCT05622136 | Liver Cancer Hepatocellular ... | Regorafenib Ora... | 18 Years - | Instituto do Cancer do Estado de São Paulo | |
| Sorafenib in Newly Diagnosed High Grade Glioma | NCT00884416 | Glioblastoma Gliosarcoma Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... | Sorafenib dose ... | 18 Years - | University Hospital, Geneva | |
| Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor | NCT01260025 | Tolerability Pharmacokinetic... Endostatin | PEDylated Recom... | 18 Years - 65 Years | Sun Yat-sen University | |
| Study to Evaluate the Safety and Anti-tumor Activity of SCC244 | NCT03466268 | Advanced Solid ... | Glumetinib for ... | 18 Years - | Haihe Biopharma Co., Ltd. | |
| Study of Simmitecan Hydrochloride in the Treatment of Advanced Solid Tumor | NCT01832298 | Advanced Solid ... | Simmitecan Hydr... | 18 Years - 65 Years | Haihe Biopharma Co., Ltd. | |
| A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients | NCT00561743 | Multiple Myelom... | Bortezomib + pe... | 18 Years - 70 Years | Janssen-Ortho Inc., Canada | |
| AZD9496 First Time in Patients Ascending Dose Study | NCT02248090 | ER+ HER2- Advan... | AZD9496 AZD9496 | 18 Years - | AstraZeneca | |
| Study of BEBT-908 in Subjects With Advanced Hematological Tumors | NCT06082596 | Relapsed or Ref... Relapsed or Ref... | BEBT-908 for in... | 18 Years - 70 Years | BeBetter Med Inc | |
| A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients | NCT00561743 | Multiple Myelom... | Bortezomib + pe... | 18 Years - 70 Years | Janssen-Ortho Inc., Canada | |
| Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors | NCT05700084 | Advanced Solid ... | Utidelone Capsu... Drug A Utidelon... Drug A Utidelon... Drug B Utidelon... Drug B Utidelon... Capecitabine Utidelone Capsu... | 18 Years - 70 Years | Beijing Biostar Pharmaceuticals Co., Ltd. | |
| Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer | NCT00615524 | Hormone-recepto... | exemestane and ... | 18 Years - | GlaxoSmithKline | |
| A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer | NCT00958477 | Prostate Cancer Bone Metastases | EMD 525797 | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors | NCT04357756 | Advanced Solid ... | YH001 Toripalimab | 18 Years - | Eucure (Beijing) Biopharma Co., Ltd | |
| Safety and Tolerability Open Label Dose Escalation Study of Acadesine in B-CLL Patients | NCT00559624 | Leukemia, B-Cel... | Acadesine | 18 Years - | Advancell - Advanced In Vitro Cell Technologies, S.A. | |
| An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia | NCT06281847 | Acute Myeloid L... Acute Myeloid L... | CCTx-001 | 18 Years - | Advesya SAS | |
| Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma | NCT00625768 | Metastatic Rena... Metastatic Mali... | AS1409 | 18 Years - | Antisoma Research | |
| Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer | NCT01972737 | Colon Cancer | Ad5-hGCC-PADRE ... | 18 Years - | Thomas Jefferson University | |
| A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer | NCT05318443 | Non-squamous No... | SIBP04 Avastin Paclitaxel Carboplatin | 18 Years - 75 Years | Shanghai Institute Of Biological Products | |
| Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor | NCT01260025 | Tolerability Pharmacokinetic... Endostatin | PEDylated Recom... | 18 Years - 65 Years | Sun Yat-sen University | |
| Ponatinib in CML Patients in Chronic Phase | NCT06119269 | Chronic Myeloid... | Therapeutic dru... Molecular Respo... | 18 Years - | University of Pisa | |
| A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) | NCT04079296 | Acute Myeloid L... Myelodysplastic... | ASP7517 | 18 Years - | Astellas Pharma Inc | |
| IPG7236 in Patients With Advanced Solid Tumors | NCT05142592 | Safety Issues Tolerability Pharmacokinetic... | IPG7236 | 18 Years - | Nanjing Immunophage Biotech Co., Ltd | |
| Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors | NCT02746081 | Solid Tumors | BAY1436032 | 18 Years - | Bayer | |
| A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors | NCT01299701 | Advanced Solid ... | ASA404 | 18 Years - | Novartis | |
| Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer | NCT01392521 | Neoplasms | Copanlisib + Re... Copanlisib + Re... | 18 Years - | Bayer | |
| Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain | NCT03435341 | Leukemia, Myelo... | 60 Years - | Celgene | ||
| AZD9496 First Time in Patients Ascending Dose Study | NCT02248090 | ER+ HER2- Advan... | AZD9496 AZD9496 | 18 Years - | AstraZeneca | |
| SB-715992 In Combination With Docetaxel In Patients With Solid Tumors | NCT00169520 | Solid Tumor Can... | docetaxel SB-715992 | 18 Years - | GlaxoSmithKline | |
| A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer | NCT05318443 | Non-squamous No... | SIBP04 Avastin Paclitaxel Carboplatin | 18 Years - 75 Years | Shanghai Institute Of Biological Products | |
| A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) | NCT04079296 | Acute Myeloid L... Myelodysplastic... | ASP7517 | 18 Years - | Astellas Pharma Inc | |
| SB-743921 In Patients With Solid Tumors | NCT00136513 | Solid Tumor Can... | SB-743921 | 18 Years - | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
